Evidence map›Paper›PMID 37251695›Full record

ArticleMathematics (Basel, Switzerland)2023

A Flexible Method for Diagnostic Accuracy with Biomarker Measurement Error.

Ching-Yun Wang, Ziding Feng

Abstract read
In one paragraph

Article in Mathematics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Biomarker data with measurement error in medical research: A literature review.Wiley interdisciplinary reviews. Computational statistics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ching-Yun WangDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 98109-1024, USA.ORCID 0000-0002-1883-333X
Ziding FengDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 98109-1024, USA.

Funding

The Early Detection Research Network: Data Management and Coordinating CenterU24CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RUTH D ETZIONI, Ziding Feng · 2010 to 2026
$75.7M
EDRN--DATA MANAGEMENT AND COORDINATING CENTERU01CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FENG, ZIDING · 2000 to 2010
$16.9M
Statistical Methods for Analysis of Tumor Heterogeneity in Genetic EpidemiologyR01CA189532 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HSU, LI · 2015 to 2023
$4.2M
Joint Modeling of Longitudinal Physical Activity and Diet Data and SurvivalR21CA239168 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI WANG, CHING-YUN · 2020 to 2021
$464k
Novel Methods for Missing Subtype Data in Colorectal CancerR03CA235122 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI WANG, CHING-YUN · 2019 to 2020
$176k
NCI NIH HHS R01 CA189532NCI NIH HHS R03 CA235122NCI NIH HHS R21 CA239168NCI NIH HHS U01 CA086368NCI NIH HHS U24 CA086368
6 · The paper itself

Abstract

Diagnostic biomarkers are often measured with errors due to imperfect lab conditions or analytic variability of the assay. The ability of a diagnostic biomarker to discriminate between cases and controls is often measured by the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, among others. Ignoring measurement error can cause biased estimation of a diagnostic accuracy measure, which results in misleading interpretation of the efficacy of a diagnostic biomarker. Existing assays available are either research grade or clinical grade. Research assays are cost effective, often multiplex, but they may be associated with moderate measurement errors leading to poorer diagnostic performance. In comparison, clinical assays may provide better diagnostic ability, but with higher cost since they are usually developed by industry. Correction for attenuation methods are often valid when biomarkers are from a normal distribution, but may be biased with skewed biomarkers. In this paper, we develop a flexible method based on skew-normal biomarker distributions to correct for bias in estimating diagnostic performance measures including AUC, sensitivity, and specificity. Finite sample performance of the proposed method is examined via extensive simulation studies. The methods are applied to a pancreatic cancer biomarker study.

Indexed as

biomarkerscorrection for attenuationmeasurement error

Identifiers

PMID37251695
PMCPMC10210524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.